Telmisartan STELLA 40 mg

Telmisartan is an orally active and specific angiotensin II receptor (type AT1) antagonist. The maximum reduction in blood pressure is generally attained 4 – 8 weeks after the start of treatment and is sustained during long-term therapy.

Pack size Box of 28 tablets, 30 tablets
Shelf-life 24 months
Composition Telmisartan
Dosage forms and strengths Tablet: 40 mg
Product code :



  • Treatment of essential hypertension.
  • Cardiovascular prevention: Reduction of cardiovascular morbidity in adults with manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or type 2 diabetes mellitus with documented target organ damage.



  • Hypertension: 40 mg once daily (may be 20 mg once daily, use of suitable dosage forms), increase to a maximum of 80 mg once daily if the target blood pressure is not achieved, may be used in combination with thiazide.
  • Cardiovascular prevention: 80 mg once daily, close monitoring of blood pressure and if appropriate adjustment of medications that lower blood pressure may be necessary.

Severe renal impairment/ haemodialysis

An initial dose of 20 mg once daily.

Mild to moderate hepatic impairment

A daily maximum dose 40 mg once daily.

Adolescents aged < 18 years

The safety and efficacy have not been established.


Telmisartan STELLA 40 mg is administered orally, taken without regard to meals.

  • Known hypersensitive to any of the active substance or excipients of the product.
  • Second and third trimesters of pregnancy and lactation.
  • Biliary obstructive disorders.
  • Severe hepatic impairment.
  • The concomitant use with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2).


  • Upper respiratory tract infection, urinary tract infection.
  • Anaemia.
  • Hyperkalemia.
  • Depression, insomnia.
  • Syncope.
  • Vertigo.
  • Bradycardia.
  • Hypotension, orthostatic hypotension.
  • Dyspnoea, cough.
  • Abdominal pain, diarrhea, dyspepsia, flatulence, vomiting.
  • Hyperhidrosis, pruritus, rash.
  • Myalgia, back pain, muscle spasms.
  • Renal impairment.
  • Chest pain, asthenia.
  • Blood creatinine increased.
  • When pregnancy is detected, telmisartan should be discontinued as soon as possible.
  • Use with caution in patients: mild to moderate hepatic impairment; bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney; vascular tone and renal function depend predominantly on the activity of the RAAS; aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy; diabetic patients; severe hypertension; ischaemic cardiovascular disease; > 70 years old.
  • Telmisartan is not to be given to patients with cholestasis; fructose intolerance.
  • When using in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended.
  • Not recommended for patients with primary aldosteronism.
  • Intravascular hypovolaemia and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhea or vomiting should be corrected before the administration of telmisartan.
  • Risk of porphyria and hyperkalaemia.
  • The dose of 80 mg contains 3.864 mg sodium. This is equivalent to approximately 0.2% of the recommended maximum daily intake of sodium for an adult.
  • Gastroduodenal ulcer can work or other stomach problems (increased risk of gastrointestinal bleeding).
  • It should be taken into account when driving vehicles or operating machinery.